IL-17 antibodies
An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.
1. An isolated polynucleotide construct that encodes an immunoglobulin heavy chain of an IL-17 antibody or antigen-binding fragment thereof comprising a heavy chain constant domain and a heavy chain variable domain (V H ), wherein said V H comprises framework regions and the three complementarity determining regions (CDRs) of SEQ ID NO:8.
2. An isolated polynucleotide construct that encodes an immunoglobulin light chain of an IL-17 antibody or antigen-binding fragment thereof comprising a light chain constant domain and a light chain variable domain (V L ), wherein said V L comprises framework regions and the three CDRs of SEQ ID NO.10.
3. An isolated polynucleotide selected from the group consisting of
a) a polynucleotide that encodes an amino acid sequence comprising SEQ ID NO:8,
b) a polynucleotide that encodes an amino acid sequence comprising SEQ ID NO:10,
c) a polynucleotide that encodes an amino acid sequence comprising the three CDRs of SEQ ID NO:8,
d) a polynucleotide that encodes an amino acid sequence comprising the three CDRs of SEQ ID NO:10,
e) a polynucleotide that encodes an amino acid sequence comprising the three CDRs of SEQ ID NO:8 and the three CDRs of SEQ ID NO:10, and
f) a polynucleotide that encodes an amino acid sequence comprising SEQ ID NO:8 and SEQ ID NO:10.
4. The polynucleotide construct according to claim 1 , wherein the three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.
5. The polynucleotide construct according to claim 1 , wherein the three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13.
6. The polynucleotide according to claim 3 ,
a) wherein the three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and wherein the three CDRs of SEQ ID NO:10 are set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or
b) wherein the three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13 and wherein the three CDRs of SEQ ID NO:10 are set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
7. An expression vector comprising the polynucleotide according to claim 3 .
8. A prokaryotic or eukaryotic host cell comprising the expression vector according to claim 7 .
9. A process for the production of an IL-17 antibody or antigen-binding fragment thereof, comprising (i) culturing the host cell of claim 8 to yield a cell culture and (ii) recovering a polypeptide expressed by the polynucleotide from said cell culture.
10. An isolated polynucleotide selected from the group consisting of
a) a polynucleotide that encodes a V H comprising SEQ ID NO:8,
b) a polynucleotide that encodes a V L comprising SEQ ID NO:10,
c) a polynucleotide that encodes a V H comprising the three CDRs of SEQ ID NO:8 and a V L comprising the three CDRs of SEQ ID NO:10, and
d) a polynucleotide that encodes a V H comprising SEQ ID NO:8 and a V L comprising SEQ ID NO:10.